Clinical Trial Update: A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ranpirnase (Onconase) in combination with pemetrexed and carboplatin for non-squamous non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• CARBOPLATIN (Carboplatin)
• ONCONASE (ranpirnase)

Snippet

Sponsor: Tamir Biotechnology, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN